Psoriasis Drugs Market Size, Share, Growth, and Industry Analysis, By Type (Biologic Drugs,Small Molecule Systemic Drugs,Tropical Therapies), By Application (TNF Alpha Inhibitors,PDE4 Inhibitors,Interleukin Inhibitors,Other Mechanisms of Action), Regional Insights and Forecast to 2035

Psoriasis Drugs Market Overview

The global Psoriasis Drugs Market is forecast to expand from USD 20691.22 million in 2026 to USD 22224.44 million in 2027, and is expected to reach USD 39372.09 million by 2035, growing at a CAGR of 7.41% over the forecast period.

The global Psoriasis Drugs Market exhibits significant scale with over 125 million people living with psoriasis globally and more than 8 million in the USA diagnosed by 2024, fueling expansion of treatment options. The Psoriasis Drugs Market Research Report reveals that approximately 47% of market share in 2024 was held by biologic therapies, while TNF-alpha inhibitors comprised about 41% of drug class share, highlighting the Psoriasis Drugs Market Size and Psoriasis Drugs Market Share dynamics. The Psoriasis Drugs Market Outlook indicates that more than 35 new drug approvals occurred globally between 2020 and 2024, contributing to the robust Psoriasis Drugs Market Growth.

The USA market alone commands a strong position, with roughly 7.5 million adults living with psoriasis and around 30% of those developing psoriatic arthritis as of 2023, according to clinical data. The Psoriasis Drugs Market Analysis for the USA shows that nearly 55% of treatment expenditures are directed toward biologic and small molecule systemic therapies, with topical therapies still used by approximately 45% of patients. US payers report that about 22% of dermatology prescriptions for psoriasis in 2024 were biosimilars and generics, reflecting shifts in the Psoriasis Drugs Market Research Report and Psoriasis Drugs Market Insights.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Approximately 62% of dermatologists cite increasing prevalence of moderate-to-severe psoriasis as a key factor.
• Major Market Restraint: Roughly 39% of healthcare providers identify high therapy cost burden as limiting treatment uptake.
• Emerging Trends: Around 27% of pipeline candidates in development target IL-17/IL-23 pathways for psoriasis indication.
• Regional Leadership: North America accounts for close to 38% of global market share in 2024.
• Competitive Landscape: About 18% of global market value in 2024 was held by top two companies.
• Market Segmentation: Biologics held nearly 49% share of the global market in 2024 while topicals made up about 19%.
• Recent Development: Biosimilar approvals increased by approximately 14% in 2023 compared to 2022.

Psoriasis Drugs Market Latest Trends

In the Psoriasis Drugs Market Trends, biologic therapies continue to dominate, with biologics capturing nearly 49% of global share in 2024 and TNF-alpha inhibitors holding roughly 41% of drug class share. Pipeline developments show that about 27% of new molecules under investigation target IL-23 and IL-17 inhibitors, reflecting significant Psoriasis Drugs Market Forecast momentum. The rise of biosimilars is noteworthy: approvals for psoriasis in 2023 grew by 14% over the previous year, and the U.S. share of biosimilar prescriptions rose to an estimated 22% in 2024, altering treatment cost structures and Psoriasis Drugs Market Outlook dynamics. Teledermatology and digital patient management platforms also influence the market, with approximately 31% of dermatology practices in 2024 offering virtual follow-up for psoriasis treatment, accelerating treatment adherence and altering distribution models.

For B2B stakeholders exploring Psoriasis Drugs Market Opportunities, the shift toward personalized medicine—led by genetic biomarkers and real-world evidence—underscores the need for strategic investment in next-gen therapies and integrated care models. Moreover, patient awareness campaigns now reach over 52% of diagnosed individuals globally, up from 38% in 2020, driving earlier diagnosis and broader treatment uptake. This expanded demand, coupled with advanced therapies and shifting reimbursement frameworks, arms the Psoriasis Drugs Market Insights with actionable signals for pharmaceutical and healthcare IT investors.

Psoriasis Drugs Market Dynamics

DRIVER

"Rising prevalence of moderate-to-severe psoriasis and increasing patient awareness."

Globally, over 125 million individuals are estimated to live with psoriasis as of 2024, and of these, approximately 30% progress to moderate-to-severe forms requiring systemic therapy. In the USA, an estimated 7.5 million adults live with psoriasis, and around 1.5 million have associated psoriatic arthritis. This increasing disease burden drives demand for advanced treatments: biologics, small molecule systemic drugs and novel topical therapies. Dermatologists report that 62% of new systemic therapy initiations in 2024 were in patients diagnosed within the past two years. The Psoriasis Drugs Market Size and Psoriasis Drugs Market Growth are directly linked to epidemiology, with expanding diagnosed population supporting wider treatment adoption. Patient awareness campaigns now cover over 52% of diagnosed cases globally, up from 38% in 2020, facilitating earlier intervention and enhancing therapy uptake. These factors combine to underpin the Psoriasis Drugs Market Analysis, with increased therapy penetration and innovation fueling growth.

RESTRAINT

"High cost of advanced therapies limiting access and reimbursement pressure."

While advancements continue, approximately 39% of healthcare providers report that the high cost of biologic treatments restricts access for eligible patients, particularly in emerging markets. In 2024, average annual cost per patient for a leading biologic was estimated to exceed USD 45,000 in developed markets, imposing budget constraints on payers and systems. In the United States, about 22% of dermatology practices cited treatment cost as a major barrier to prescribing advanced systemic therapy. Additionally, reimbursement restrictions apply: around 34% of payers require prior biologic failure before covering newer agents. These constraints affect uptake rates in the Psoriasis Drugs Market Share and slow down adoption in certain geographies. They also restrict expansion into emerging regions, where average healthcare spend per capita is lower, thereby limiting Psoriasis Drugs Market Outlook potential in those areas.

OPPORTUNITY

"Growth in personalized therapies, biosimilars and emerging markets."

The Psoriasis Drugs Market Opportunities are broad: biosimilar launches increased by about 14% in 2023 versus 2022, providing lower-cost options and widening access. Emerging markets in Asia-Pacific represent rising potential: China, India, South Korea and Australia contributed to approximately 22% of global incremental volume in 2023, and patient diagnosis campaigns now cover over 40% of adult populations in these regions. Personalized medicine is gaining traction: about 19% of new drug candidates in the pipeline incorporated biomarker stratification for psoriasis in 2024. Furthermore, about 28% of payers globally now support outcome-based reimbursement models for advanced psoriasis therapies, enabling broader uptake and enhanced value. These factors offer substantial room for growth, particularly for companies that can navigate regulatory approval and market access in high-growth geographies, enhancing the Psoriasis Drugs Market Growth and Psoriasis Drugs Market Forecast for the next decade.

CHALLENGE

"Competitive intensity and complex regulatory landscape hamper entry and differentiation."

The Psoriasis Drugs Market Challenges include dense competition: biologics captured nearly 49% share in 2024, leaving other segments needing novel differentiation to gain share. Patent expirations and biosimilar introductions, especially in the TNF-alpha segment (~41% share in 2024), widen competition, compressing margins. Regulatory pathways remain stringent: roughly 34% of new psoriasis drug applications in 2023 required additional long-term safety data before approval in major markets. Market entry in emerging regions is also complicated by supplier-registration delays—on average 12–18 months longer than in developed markets. These headwinds increase time-to-market and cost for new entrants and create pressure on pricing and reimbursement, affecting vendor strategies captured in the Psoriasis Drugs Market Analysis and Psoriasis Drugs Market Industry Report.

Psoriasis Drugs Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Biologic Drugs: Biologic drugs represented approximately 49% of the global psoriasis drugs market share in 2024, reflecting dominance of protein-based targeted therapies. These therapies accounted for about 52% of new systemic therapy initiations in 2024, and their share of total prescriptions in moderate-to-severe psoriasis rose from 45% in 2022 to 48% in 2024. The Psoriasis Drugs Market Size for biologics thus remains substantial. Pricing for biotherapeutics often exceeded USD 40,000 annual therapy cost in major markets, and biologics captured about 55% of total annual treatment expenditure despite being used by less than one third of diagnosed patients.

Small Molecule Systemic Drugs: Small molecule systemic drugs formed approximately 24% of market volume in 2024, used particularly in patients unable to access biologics or in countries with reimbursement barriers. Oral systemic therapies accounted for about 16% of all systemic therapy initiations in 2024, while injectable or infusion biologics held the remainder. Among small molecules, PDE4 inhibitors and JAK inhibitors are prominent; usage increased by around 9% in 2023 over 2022. These therapies typically cost 25-40% less than biologics in major markets and are being adopted in emerging regions.

Topical Therapies: Topical therapies accounted for approximately 19% of the total global market share in 2024, used extensively in mild and moderate psoriasis cases. Topicals include corticosteroids, vitamin-D analogues and combination creams; usage data show that more than 60% of diagnosed psoriasis patients receive some form of topical therapy at first line, and about 45% continue topicals at some point even after systemic therapy initiation. In 2024, topical therapy sales increased by around 5% versus 2023, reflecting growth in maintenance treatment and adjunctive use.

BY APPLICATION

TNF Alpha Inhibitors: TNF-alpha inhibitors comprised roughly 41% of the global drug-class share in 2024, making them the largest mechanism-of-action segment historically. They remain widely used in moderate-to-severe psoriasis and psoriatic arthritis, with approximately 1.5 million patients treated worldwide as of 2024. Initiation of TNF inhibitors in 2024 comprised about 28% of new systemic starts, down from 35% in 2020 as newer IL-23/IL-17 agents took share. Biosimilar versions of TNF-alpha inhibitors penetration rose from 17% in 2022 to 23% in 2024.

PDE4 Inhibitors: PDE4 inhibitors represented about 9% of the mechanism-of-action share in 2024, used primarily for mild-to-moderate plaque psoriasis. Their usage increased by approximately 12% year-on-year in 2023, and global patient count for PDE4 usage exceeded 0.8 million as of end 2024. These oral agents offer fewer contraindications and broader eligibility, making them particularly relevant in emerging markets and older populations.

Interleukin Inhibitors: Interleukin inhibitors (IL-17/IL-23/IL-12) captured about 28% share of drug-class usage in 2024 and comprised around 38% of new systemic therapy initiations in 2024. Pipeline data show that roughly 27% of new psoriasis molecular entities under development target interleukin pathways. In 2024, global patient count on IL-23 therapies exceeded 0.9 million and on IL-17 therapies exceeded 0.75 million.

Other Mechanisms of Action: The “Other Mechanisms of Action” category, including JAK inhibitors, TYK2 inhibitors, and novel small molecules, accounted for approximately 22% of pipeline volume in 2024 and about 11% of current global usage. Patient counts using these mechanisms exceeded 0.6 million in 2024, with a year-on-year volume growth of around 15%.

Psoriasis Drugs Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

In North America, the Psoriasis Drugs Market Share stood at roughly 38% in 2024, with the United States contributing approximately 30% of global share and the remainder from Canada and Mexico. Approximately 7.5 million adults in the U.S. are living with psoriasis, and dermatology practices report that 55% of moderate-to-severe patients receive systemic therapy. Market uptake of biologics exceeded 48% in moderate-to-severe cohorts in 2024, while biosimilar penetration reached about 22%. Private and public payers in the U.S. designated over 27% of dermatology drug expenditure to psoriasis therapies in 2024. In Canada, psoriasis prevalence is estimated at 2% of adults, and systemic therapy uptake is approximately 21% of diagnosed cases, with biosimilars beginning to penetrate in 2024 with about 18% dispensing.

The North America Psoriasis Drugs Market is valued at approximately USD 7,400 million in 2025, accounting for nearly 38.4% of the global market share, with consistent growth aligning to the overall 7.41% expansion rate.

North America – Major Dominant Countries in the Psoriasis Drugs Market

• The United States leads the North American Psoriasis Drugs Market with an estimated value of USD 6,200 million in 2025, representing about 83.1% of the regional market share, driven by advanced biologic adoption and growing patient awareness.
• Canada holds the second-largest position in the North American market, valued at around USD 640 million in 2025 with 8.6% regional share, supported by rising dermatological healthcare infrastructure and increased access to biosimilar therapies.
• Mexico’s psoriasis drugs segment is projected to reach approximately USD 350 million in 2025, accounting for 4.7% of the regional market share, driven by expanding healthcare coverage and demand for affordable small molecule therapies.
• Puerto Rico is estimated to contribute around USD 150 million to the North American market in 2025, with a 2.0% share, supported by a growing number of dermatology treatment centers and improved biologic drug imports.
• The Bahamas represents a smaller but emerging psoriasis drug market, valued near USD 60 million in 2025, equivalent to 0.8% regional share, primarily driven by healthcare modernization and regional partnerships with U.S. pharmaceutical distributors.

Europe

In Europe, the Psoriasis Drugs Market Share reached approximately 30% in 2024 across Western Europe, with Germany, United Kingdom, France, Italy and Spain accounting for roughly 65% of the region’s share. Germany alone captured approximately 29% of European volume in 2024, with systemic therapy penetration of about 34% in diagnosed moderate-to-severe patients. United Kingdom uptake reached about 28% of eligible patients, while biosimilar acceptance in the UK averaged 25% of systemic psoriasis prescriptions in 2024. France saw biosimilar penetration of roughly 22%, and Italy approximately 18%. Average annual cost per biologic therapy in Europe is around USD 38,000 in 2024, with regional growth of systemic therapy initiations at about 8% year-on-year in major markets.

The Europe Psoriasis Drugs Market is projected to hold around USD 5,585 million in 2025, representing 29% of global share, with stable demand for biologics and increasing uptake of biosimilars driving consistent regional growth at 7.41%.

Europe – Major Dominant Countries in the Psoriasis Drugs Market

• Germany dominates the European Psoriasis Drugs Market with an estimated value of USD 1,220 million in 2025, accounting for about 21.8% regional share, driven by a large patient base and high biologic treatment penetration.
• The United Kingdom stands as the second-largest contributor, valued at approximately USD 860 million in 2025 with a 15.4% share, reflecting robust healthcare funding and accelerated acceptance of biosimilar and IL-17 inhibitor therapies.
• France’s psoriasis drug market is expected to reach around USD 650 million in 2025, with 11.6% of the European share, boosted by government reimbursement schemes and a growing preference for interleukin inhibitor treatments.
• Italy holds an estimated market value of USD 560 million in 2025, accounting for 10% of the European segment, supported by increasing prescriptions for biologic drugs and rising dermatological awareness across hospitals and clinics.
• Spain’s psoriasis drug market is forecast to reach about USD 470 million in 2025, representing 8.4% of regional share, driven by expanding healthcare reforms, access to affordable PDE4 inhibitors, and early-stage biologic adoption programs.

Asia-Pacific

The Asia-Pacific region accounted for approximately 22% of the global Psoriasis Drugs Market Share in 2024, and patient diagnosis rates grew by around 6% annually from 2020-24. China represents about 35% of the regional volume, India about 17%, Japan about 14%, South Korea around 10%, and Australia roughly 6%. In China, diagnosed adult prevalence is estimated at approximately 0.44% to 2.8%, and systemic therapy uptake among moderate-to-severe patients stood at about 15% in 2024. India’s diagnosed adult population is estimated at about 5.3 million, with systemic therapy penetration near 9% and biosimilar usage approximating 30% of prescriptions. Japan reports approximately 1.0 million diagnosed adults and 29% systemic therapy uptake. South Korea’s uptake among moderate-to-severe patients is about 13% and biosimilar adoption near 22%.

The Asia Psoriasis Drugs Market is estimated at USD 3,467 million in 2025, capturing roughly 18% of the global market share, fueled by rising diagnosis rates, healthcare infrastructure expansion, and increasing adoption of biologics and biosimilars across key economies.

Asia – Major Dominant Countries in the Psoriasis Drugs Market

• China leads the Asian Psoriasis Drugs Market with an estimated valuation of USD 1,230 million in 2025, accounting for 35.5% regional share, driven by high patient prevalence and significant investment in domestic biosimilar manufacturing.
• India’s psoriasis drugs segment is valued at approximately USD 610 million in 2025, representing 17.6% of the regional share, supported by increasing awareness campaigns, generic drug production, and wider dermatological treatment access.
• Japan’s market is expected to reach USD 480 million in 2025, with 13.9% regional share, propelled by the high adoption of interleukin inhibitors and the country’s advanced clinical dermatology infrastructure.
• South Korea’s psoriasis drugs market stands at an estimated USD 350 million in 2025, capturing 10.1% of Asia’s share, due to growing government support for biosimilar approvals and digital dermatology integration.
• Australia holds a projected market value of USD 260 million in 2025, contributing 7.5% of Asia’s regional share, benefiting from early biologic adoption, telemedicine growth, and an expanding dermatology care network.

Middle East & Africa

In the Middle East & Africa, the Psoriasis Drugs Market Share is approximately 10% of the global total in 2024, and systemic therapy uptake among diagnosed patients is lower, averaging around 8%. Within this region, Saudi Arabia accounts for about 32% of regional volume, United Arab Emirates around 26%, South Africa about 18%, Egypt roughly 14% and Nigeria approximately 10%. In Saudi Arabia, diagnosed adult prevalence is estimated at about 2.3%, with systemic therapy uptake in moderate-to-severe cases near 12% in 2024. The UAE reports biosimilar adoption of around 19% of prescriptions. South Africa sees systemic therapy penetration near 9% and high growth in biosimilar supply chains. Egypt’s uptake among eligible patients is approximately 7%, and Nigeria around 6%, though diagnosis growth is above 5% annual in several markets.

The Middle East and Africa Psoriasis Drugs Market is valued at approximately USD 1,541 million in 2025, representing 8% of the global share, with rapid infrastructure development, healthcare investment, and patient diagnosis driving regional market growth at 7.41%.

Middle East and Africa – Major Dominant Countries in the Psoriasis Drugs Market

• Saudi Arabia leads the Middle East and Africa market with an estimated valuation of USD 490 million in 2025, representing 31.8% regional share, driven by increasing healthcare spending and expansion of biologic therapy distribution.
• The United Arab Emirates is projected at USD 400 million in 2025, capturing about 26% regional share, supported by a surge in dermatology clinic investments and the availability of multinational pharmaceutical brands.
• South Africa’s psoriasis drugs market is valued at roughly USD 280 million in 2025, making up 18.2% regional share, driven by urbanization, public health initiatives, and increased accessibility to biologics and PDE4 inhibitors.
• Egypt holds an estimated value of USD 215 million in 2025, accounting for 14% of the regional share, supported by a growing network of dermatology hospitals and expanding domestic pharmaceutical capabilities.
• Nigeria’s psoriasis drugs market stands at approximately USD 156 million in 2025, capturing 10.1% of regional share, with growth attributed to improving diagnostic infrastructure and gradual introduction of affordable small molecule drugs.

List of Top Psoriasis Drugs Companies

• UCB
• Johnson & Johnson
• Takeda Pharmaceutical
• Eli Lilly & Company
• Janssen Biotech
• Amgen
• AbbVie
• Biogen
• Novartis AG
• Stiefel Laboratories
• AstraZeneca
• Pfizer
• Celgene Corporation
• AbbVie (duplicate)
• Merck

Top Two Companies With Highest Share

• AbbVie (held approximately 21% of leading biologic therapy market share in 2024)
• Johnson & Johnson (controlled around 16% of system-wide psoriasis biologic prescriptions in 2024)

Investment Analysis and Opportunities

Investment flows into the Psoriasis Drugs Market exceeded USD 6 billion in research and development funding in 2023, with over 120 ongoing clinical trials targeting psoriasis and psoriatic arthritis. For B2B investors and pharmaceutical companies reviewing the Psoriasis Drugs Market Forecast, the expansion into emerging markets is notable—Asia-Pacific incremental value added in 2023 surpassed USD 1.2 billion, reflecting rising patient diagnosis and therapy uptake. Partnerships and acquisitions remain active: approximately 18% of deals in dermatology in 2023 focused on psoriasis therapeutics. Biosimilar launches increased by 14% in 2023, and pipeline data show 27% of new candidate drugs targeting IL-23/IL-17 pathways, offering strong Psoriasis Drugs Market Opportunities. Also, about 28% of payers globally now implement outcome-based contracting for psoriasis therapies, enhancing access and reducing budget impact, thereby attracting institutional investors to manufacturers of next-gen therapies. The lower-cost small molecule segment grew by nearly 12% in 2023, and emerging markets expanded diagnosis campaigns by roughly 6% per annum—these factors create multi-front investment opportunities in manufacturing, distribution, digital patient engagement and biosimilar supply chains.

New Product Development

In the Psoriasis Drugs Market New Product Development arena, several advanced therapies entered late-stage development in 2023-24: for example, approximately 19% of new molecular entities in the pipeline incorporated biomarker stratification and personalized medicine approaches for psoriasis. One leading interleukin-23 inhibitor registered a Phase III study with over 1,600 participants, anticipating approval in multiple geographies. Biosimilar launches increased with the first U.S. biosimilar to a major IL-12/23 inhibitor being prepared in 2025. Additionally, novel oral JAK/ TYK2 inhibitors saw utilization rate increases of around 15% globally in 2023 compared to 2022. Telemedicine-enabled eczema/psoriasis combination therapies are being integrated in about 31% of dermatology practices, engaging digital health platforms alongside clinical drugs. These innovations underpin the Psoriasis Drugs Market Research Report and provide insights into evolving product pipelines and competitive positioning. For pharmaceutical firms analysing the Psoriasis Drugs Market Insights, these development trends signal where next-wave therapy adoption will cluster and where strategic product launches can deliver differentiated value.

Five Recent Developments

• A major manufacturer announced the expansion of its IL-23 inhibitor to include pediatric plaque psoriasis indication, enrolling over 350 children in the trial in 2024.
• A biosimilar to a leading TNF-alpha inhibitor achieved regulatory approval in the United States in early 2025, marking the first biosimilar to enter the U.S. psoriasis market, reducing treatment cost for approximately 220 000 eligible patients.
• A JAK-inhibitor oral therapy achieved a 56% skin-clearance (PASI 75) rate at Week 12 in a Phase III trial with 820 participants in 2024, underscoring efficacy in moderate-to-severe psoriasis.
• A digital therapeutic partnered with a biologic manufacturer launched a remote monitoring and adherence platform in 2024, used by approximately 38% of dermatology clinics, improving treatment-continuation rates by 17%.
• A dermatology alliance across five countries rolled out an outcome-based contracting model for psoriasis therapies in late 2023, covering an estimated 185 000 patients and tying reimbursement to skin-clearance outcomes above 70% within 6 months.

Report Coverage of Psoriasis Drugs Market

The scope of this Psoriasis Drugs Market Report covers global and regional markets, including segmentation by drug type (biologics, small molecule systemic drugs, topical therapies) and mechanism of action (TNF-alpha inhibitors, PDE4 inhibitors, interleukin inhibitors, other mechanisms). It includes data from over 1 200 clinical trials, analysis of pipeline candidates (over 350 active agents), and evaluation of over 180 country-level markets. The report integrates more than 2,600 dermatology practice surveys, 520 payer-policy assessments and 460 biosimilar approval events between 2020-24. Geographic coverage spans North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America, with region-specific therapy uptake data, diagnosis rates and reimbursed patient volumes. For B2B stakeholders analysing the Psoriasis Drugs Market Analysis, Psoriasis Drugs Market Growth potential, and Psoriasis Drugs Market Insights, this industry report offers actionable intelligence on therapy adoption, investment trends, competitor positioning, segmentation performance and regional opportunities.

Psoriasis Drugs Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 20691.22 Million in 2026
Market Size Value By	USD 39372.09 Million by 2035
Growth Rate	CAGR of 7.41% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Biologic Drugs Small Molecule Systemic Drugs Tropical Therapies By Application : TNF Alpha Inhibitors PDE4 Inhibitors Interleukin Inhibitors Other Mechanisms of Action
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample